Assessment and monitoring tumor vascularity with contrast-enhanced ultrasound maximum intensity persistence imaging

Investigative Radiology

Volumn 46, Issue 3, 2011, Pages 187-195

  Pysz, Marybeth A ^a   Foygel, Kira ^a   Panje, Cedric M ^a   Needles, Andrew ^b   Tian, Lu ^a   Willmann, Jürgen K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VisualSonics   (Canada)

Author keywords

antiangiogenic treatment; colon cancer; maximum intensity persistence; microbubbles; ultrasound

Indexed keywords

ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; CONTRAST MEDIUM; VASCULOTROPIN ANTIBODY;

ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; COLON CANCER; CONCENTRATION (PARAMETERS); CONTRAST ENHANCEMENT; CONTROLLED STUDY; DENSITY; EXPERIMENTAL STUDY; HUMAN; HUMAN CELL; IMAGING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAXIMUM INTENSITY PERSISTENCE IMAGING; MICROBUBBLE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RELIABILITY; SIGNAL NOISE RATIO; SUBCUTANEOUS TISSUE TUMOR; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 79751536352     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181f9202d     Document Type: Article

References (34)

1. Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. Oncologist. 2005;10:92-103. (Pubitemid 40261948)
2. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987-989. (Pubitemid 32937367)
3. Willmann JK, van Bruggen N, Dinkelborg LM, et al. Molecular imaging in drug development. Nat Rev Drug Discov. 2008;7:591-607. (Pubitemid 351927724)
4. Barrett T, Brechbiel M, Bernardo M, et al. MRI of tumor angiogenesis. J Magn Reson Imaging. 2007;26:235-249. (Pubitemid 47257720)
5. Charnley N, Donaldson S, Price P. Imaging angiogenesis. Methods Mol Biol. 2009;467:25-51.
6. Rief M, Huppertz A, Asbach P, et al. Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement. Invest Radiol. 2010;45:565-571.
7. Broumas AR, Pollard RE, Bloch SH, et al. Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow. Invest Radiol. 2005;40:134-147. (Pubitemid 40289440)
8. Miles KA. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol. 1999;30:198-205. (Pubitemid 29343737)
9. Raatschen HJ, Fu Y, Brasch RC, et al. In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. Invest Radiol. 2009;44:265-270.
10. Lassau N, Chami L, Benatsou B, et al. Dynamic contrast-enhanced ultra-sonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol. 2007;17(suppl 6):F89-F98. (Pubitemid 351337913)
11. Lassau N, Koscielny S, Opolon P, et al. Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo. Invest Radiol. 2001;36:50-55. (Pubitemid 32064170)
12. Magnon C, Galaup A, Rouffiac V, et al. Dynamic assessment of antiangio-genic therapy by monitoring both tumoral vascularization and tissue degeneration. Gene Ther. 2007;14:108-117. (Pubitemid 46043817)
13. Perini R, Choe R, Yodh AG, et al. Non-invasive assessment of tumor neovasculature: techniques and clinical applications. Cancer Metastasis Rev. 2008;27:615-630.
14. Lavisse S, Lejeune P, Rouffiac V, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol. 2008;43:100-111.
15. Averkiou M, Lampaskis M, Kyriakopoulou K, et al. Quantification of tumor microvascularity with respiratory gated contrast enhanced ultrasound for monitoring therapy. Ultrasound Med Biol. 2010;36:68-77.
16. Wilson SR, Jang HJ, Kim TK, et al. Real-time temporal maximum-intensity-projection imaging of hepatic lesions with contrast-enhanced sonography. Am J Roentgenol. 2008;190:691-695. (Pubitemid 351304513)
17. Lamuraglia M, Bridal SL, Santin M, et al. Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives. Crit Rev Oncol Hematol. 2010;73:202-212.
18. Richardson IE. H. 264 and MPEG-4 Video Compression: Video Coding for Next-Generation Multimedia. Chichester, United Kingdom: John Wiley & Sons Ltd.; 2003.
19. Pysz MA, Foygel K, Rosenberg J, et al. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology. 2010;256:519-527.
20. Willmann JK, Cheng Z, Davis C, et al. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology. 2008;249:212-219.
21. Fuh G, Wu P, Liang WC, et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem. 2006;281:6625-6631. (Pubitemid 43847597)
22. Hoyt K, Warram JM, Umphrey H, et al. Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. J Ultrasound Med. 2010;29:577-585.
23. Weidner N. Chapter 14. Measuring intratumoral microvessel density. Methods Enzymol. 2008;444:305-323.
24. Hwang M, Niermann KJ, Lyshchik A, et al. Sonographic assessment of tumor response: from in vivo models to clinical applications. Ultrasound Q. 2009; 25:175-183.
25. Delorme S, Krix M. Contrast-enhanced ultrasound for examining tumor biology. Cancer Imaging. 2006;6:148-152.
26. Ignee A, Jedrejczyk M, Schuessler G, et al. Quantitative contrast enhanced ultrasound of the liver for time intensity curves-Reliability and potential sources of errors. Eur J Radiol. 2010;73:153-158.
27. Seiler GS, Ziemer LS, Schultz S, et al. Dose-response relationship of ultrasound contrast agent in an in vivo murine melanoma model. Cancer Imaging. 2007;7:216-223.
28. Wei K, Jayaweera AR, Firoozan S, et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998;97:473-483. (Pubitemid 28090220)
29. Sehgal CM, Cary TW, Arger PH, et al. Delta-projection imaging on contrast-enhanced ultrasound to quantify tumor microvasculature and perfusion. Acad Radiol. 2009;16:71-78.
30. Palmowski M, Lederle W, Gaetjens J, et al. Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound. Eur J Radiol. 2010;75:e149-e153.
31. Barugel ME, Vargas C, Krygier Waltier G. Metastatic colorectal cancer: recent advances in its clinical management. Expert Rev Anticancer Ther. 2009;9:1829-1847.
32. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400. (Pubitemid 38618122)
33. Needles A, Mehi J, Arditi M, et al. Nonlinear contrast agent imaging with a linear array based micro-ultrasound system. In: IEEE Ultrasonics Symposium; September 20-23,2009; Rome, Italy.
34. Feingold S, Gessner RC, Guracar IM, et al. Quantitative volumetric perfusion mapping of the microvasculature using contrast ultrasound. Invest Radiol. 2010;45:669-674.